ADVFN Logo ADVFN

We could not find any results for:
Make sure your spelling is correct or try broadening your search.

Trending Now

Toplists

It looks like you aren't logged in.
Click the button below to log in and view your recent history.

Hot Features

Registration Strip Icon for smarter Trade smarter, not harder: Unleash your inner pro with our toolkit and live discussions.
Thiogenesis Therapeutics Corp

Thiogenesis Therapeutics Corp (TTI)

0.59
0.00
(0.00%)
Closed December 25 3:00PM

Professional-Grade Tools, for Individual Investors.

Key stats and details

Current Price
0.59
Bid
0.59
Ask
0.65
Volume
-
0.00 Day's Range 0.00
0.52 52 Week Range 1.06
Market Cap
Previous Close
0.59
Open
-
Last Trade
Last Trade Time
Financial Volume
-
VWAP
-
Average Volume (3m)
15,861
Shares Outstanding
44,570,000
Dividend Yield
-
PE Ratio
-1.95
Earnings Per Share (EPS)
-0.11
Revenue
-
Net Profit
-5.03M

About Thiogenesis Therapeutics Corp

Sector
Pharmaceutical Preparations
Industry
Unit Inv Tr, Closed-end Mgmt
Headquarters
Toronto, Ontario, Can
Founded
2022
Thiogenesis Therapeutics Corp is listed in the Pharmaceutical Preparations sector of the TSX Venture Exchange with ticker TTI. The last closing price for Thiogenesis Therapeutics was $0.59. Over the last year, Thiogenesis Therapeutics shares have traded in a share price range of $ 0.52 to $ 1.06.

Thiogenesis Therapeutics currently has 44,570,000 shares outstanding. The market capitalization of Thiogenesis Therapeutics is $26.30 million. Thiogenesis Therapeutics has a price to earnings ratio (PE ratio) of -1.95.

TTI Latest News

TSX Venture Exchange Stock Maintenance Bulletins

TSX Venture Exchange Stock Maintenance Bulletins Canada NewsWire VANCOUVER, BC, Dec. 29, 2023 VANCOUVER, BC, Dec. 29, 2023 /CNW/ - TSX VENTURE COMPANIES BULLETIN V2023-0432 BEDFORD METALS CORP...

L'OCRCVM permet la reprise de la négociation - TTI

L'OCRCVM permet la reprise de la négociation - TTI Canada NewsWire VANCOUVER, BC, le 12 avril 2022 VANCOUVER, BC, le 12 avril 2022 /CNW/ - Reprise des négociations pour : Société :...

IIROC Trading Resumption - TTI

IIROC Trading Resumption - TTI Canada NewsWire VANCOUVER, BC, April 12, 2022 VANCOUVER, BC, April 12, 2022 /CNW/ - Trading resumes in: Company: Thiogenesis Therapeutics, Corp. (Formerly:  Rozdil...

Trillium Therapeutics Receives Prestigious National Award

TORONTO, ONTARIO--(Marketwired - June 13, 2014) - Trillium Therapeutics Inc. ("TTI") (TSX:TR)(OTCQX:SCTPF), an immuno-oncology company developing innovative therapies for the treatment of cancer...

Stem Cell Therapeutics Changes Its Name to Trillium Therapeutics Inc.

TORONTO, ONTARIO--(Marketwired - June 2, 2014) - Stem Cell Therapeutics Corp. ("SCT") (TSX:SSS)(OTCQX:SCTPF), an immuno-oncology company developing innovative therapies for the treatment of...

IIROC Trading Halt - TTI

IIROC Trading Halt - TTI #ReleaseContent TABLE { BORDER-COLLAPSE: collapse } TR.cnwUnderlinedCell TD { BORDER-BOTTOM: #000000 1px solid } TR.cnwDoubleUnderlinedCell TD { BORDER-BOTTOM:...

TSX Venture Exchange Cease Trade Order

TSX Venture Exchange Cease Trade Order #ReleaseContent TABLE { BORDER-COLLAPSE: collapse } TR.cnwUnderlinedCell TD { BORDER-BOTTOM: #000000 1px solid } TR.cnwDoubleUnderlinedCell TD {...

Investment Industry Regulatory Organization of Canada Trading Resumption – TTI

VANCOUVER, Jan. 23, 2012 /CNW/ - Trading resumes in: Company: TRANSGLOBE INTERNET & TELECOM CO., LTD. TSX-Venture Symbol: TTI Resumption: At the open January 24, 2012 IIROC can...

Investment Industry Regulatory Organization of Canada Trading Halt – TTI

VANCOUVER, Jan. 16, 2012 /CNW/ - The following issues have been halted by IIROC: Company: TransGlobe Internet & Telecom Co., Ltd. TSX-Venture Symbol: TTI Reason:Failure to...

PeriodChangeChange %OpenHighLowAvg. Daily VolVWAP
1000.590.620.58120600.60049751CS
4-0.08-11.94029850750.670.680.58179230.61991491CS
12-0.08-11.94029850750.670.690.52158610.61080927CS
26-0.12-16.90140845070.710.80.52191110.67387299CS
52-0.14-19.17808219180.731.060.52173610.71502477CS
1560.1947.50.41.060.375171860.65716254CS
2600.1947.50.41.060.375171860.65716254CS

TTI - Frequently Asked Questions (FAQ)

What is the current Thiogenesis Therapeutics share price?
The current share price of Thiogenesis Therapeutics is $ 0.59
How many Thiogenesis Therapeutics shares are in issue?
Thiogenesis Therapeutics has 44,570,000 shares in issue
What is the market cap of Thiogenesis Therapeutics?
The market capitalisation of Thiogenesis Therapeutics is CAD 26.3M
What is the 1 year trading range for Thiogenesis Therapeutics share price?
Thiogenesis Therapeutics has traded in the range of $ 0.52 to $ 1.06 during the past year
What is the PE ratio of Thiogenesis Therapeutics?
The price to earnings ratio of Thiogenesis Therapeutics is -1.95
What is the reporting currency for Thiogenesis Therapeutics?
Thiogenesis Therapeutics reports financial results in CAD
What is the latest annual profit for Thiogenesis Therapeutics?
The latest annual profit of Thiogenesis Therapeutics is CAD -5.03M
What is the registered address of Thiogenesis Therapeutics?
The registered address for Thiogenesis Therapeutics is 4 KING STREET WEST, STE. 401, TORONTO, ONTARIO, M5H 1B6
What is the Thiogenesis Therapeutics website address?
The website address for Thiogenesis Therapeutics is www.thiogenesis.com
Which industry sector does Thiogenesis Therapeutics operate in?
Thiogenesis Therapeutics operates in the UNIT INV TR, CLOSED-END MGMT sector

Movers

View all
  • Most Active
  • % Gainers
  • % Losers
SymbolPriceVol.
AAAAAuralite Investments Inc
$ 0.265
(0.00%)
0
AAA.PFirst Tidal Acquisition Corp
$ 0.04
(0.00%)
0
AAAlba Minerals Ltd
$ 0.03
(0.00%)
0
A.HArmor Minerals Inc
$ 0.30
(0.00%)
0
AArmor Minerals Inc
$ 0.45
(0.00%)
0
AAAAAuralite Investments Inc
$ 0.265
(0.00%)
0
AAA.PFirst Tidal Acquisition Corp
$ 0.04
(0.00%)
0
AAAlba Minerals Ltd
$ 0.03
(0.00%)
0
A.HArmor Minerals Inc
$ 0.30
(0.00%)
0
AArmor Minerals Inc
$ 0.45
(0.00%)
0
CPLCopper Lake Resources Ltd
$ 0.01
(0.00%)
11.98M
WCUWorld Copper Ltd
$ 0.05
(-23.08%)
5.75M
QNCQuantum Emotion Corp
$ 0.66
(24.53%)
4.89M
THRMTherma Bright Inc
$ 0.035
(16.67%)
2.64M
CANSWildpack Beverage Inc
$ 0.01
(100.00%)
2.12M

TTI Discussion

View Posts
CommodityCoverage CommodityCoverage 2 days ago
'A Prodrug for Mito-Dysfunction' Offering 113% Upside Potential - Thiogenesis Therapeutics (TTI.v) Research Report Summary: https://x.com/StckMasterFlash/status/1871347807430291939

Focused on a cutting-edge approach to rare disease treatment with a solid foundation for growth, Thiogenesis Therapeutics (TTI.v) is a clinical-stage biotech company advancing its lead product TTI-0102 to treat rare mitochondrial diseases including MELAS and Leigh Syndrome (LS). TTI offers a high-risk, high-reward investment opportunity, driven by its innovative approach to treating rare mitochondrial diseases and the potential for substantial market penetration across its targeted indications.
👍️0
CommodityCoverage CommodityCoverage 5 days ago
Focused on a cutting-edge approach to rare disease treatment with a solid foundation for growth, Thiogenesis Therapeutics (TTI.v) is a clinical-stage biotech company advancing its lead product TTI-0102 to treat rare mitochondrial diseases MELAS and Leigh Syndrome (LS): https://x.com/StckMasterFlash/status/1866620308544786857

MELAS: Phase 2 trial begins in early 2025 (Netherlands & France) targeting 15,000 U.S. and 20,000 EU patients.
Leigh Syndrome: IND filing planned for early 2025 for this severe, untreatable disorder affecting 1 in 40,000 births.
👍️0
CommodityCoverage CommodityCoverage 2 weeks ago
Yesterday, Thiogenesis Therapeutics (TTI.v) presented significant updates on its two clinical programs that are advancing its lead product, TTI-0102 which aims to address oxidative stress and improve outcomes for rare, debilitating conditions that affect a range of patients worldwide: https://x.com/StckMasterFlash/status/1866620308544786857

Having submitted its Clinical Trial Application Part II in Europe, TTI plans to launch a Phase 2 trial in early 2025 in the Netherlands and France for MELAS, focusing on physical endurance and biomarker analysis in 12 patients. For Leigh Syndrome, TTI collaborated with a leading U.S. children’s hospital and engaged in a pre-IND meeting with the FDA, paving the way for an IND submission and a Phase 2a trial in early 2025.
👍️0
CommodityCoverage CommodityCoverage 2 weeks ago
Today, Thiogenesis Therapeutics (TTI.v), a clinical-stage biotechnology company, presented updates on its two clinical programs for mitochondrial diseases during the UMDF "Bench-to-Bedside" webcast: https://www.newsfilecorp.com/release/233143/Thiogenesis-Announces-Presentation-on-UMDF-Webcast-Featuring-Clinical-Trials-in-Mitochondrial-Disease

TTI is advancing its lead product, TTI-0102, with promising applications in treating MELAS, a rare disorder affecting 15,000 patients in the U.S. and 20,000 in the EU, and Leigh Syndrome (LS), which is diagnosed in infancy and affects 1 in 40,000 births (More info: https://www.reddit.com/r/RichTogether/comments/1gvx18y/with_45m_in_the_bank_a_low_burn_rate_strong/)
👍️0
CommodityCoverage CommodityCoverage 3 weeks ago
Last week, clinical-stage biotech company Thiogenesis Therapeutics (TTI.v) announced attaining DTC eligibility in the US, facilitating electronic settlement of its common shares; a significant milestone aligning with the company's plans for a future U.S. listing: https://www.newsfilecorp.com/release/231667/Thiogenesis-Announces-DTC-Eligibility-in-the-U.S.-and-Other-Updates 

Targeting pediatric diseases with unmet medical needs and zero approved drugs or treatments, TTI is focused on developing novel thiol-based compounds to address mitochondrial dysfunction and its related diseases -  a substantial addressable market as mitochondrial diseases collectively affect millions worldwide, with very few effective therapies currently available: https://x.com/StckMasterFlash/status/1859742853578076171
👍️0
CommodityCoverage CommodityCoverage 1 month ago
Targeting pediatric diseases with unmet medical needs and zero approved drugs or treatments, Thiogenesis Therapeutics (TTI.v) is a biopharmaceutical company focused on developing novel thiol-based compounds to address mitochondrial dysfunction and its related diseases: https://drive.google.com/file/d/1Obahg9CXnD__6WbReUT93Sgzu6C9EoD_/view

Representing a growing market segment in the pharmaceutical industry, estimates suggest the mitochondrial disease therapies market to be worth USD 1,817 million by 2030. Thus,

By leveraging its innovative compounds and focusing on pediatric diseases with no approved therapies, TTI has the potential to make significant strides in addressing critical gaps alongside addressing multiple indications within this growing market, presenting significant commercial and therapeutic opportunities.
👍️0
CommodityCoverage CommodityCoverage 1 month ago
Insightful breakdown of Thiogenesis Therapeutics (TTI.v) and the market opportunity its taking advantage of by focusing on pediatric diseases with unmet medical needs including pediatric NASH which currently has zero approved drugs or treatments: https://x.com/airic101/status/1856816752128143615
👍️0
CommodityCoverage CommodityCoverage 1 month ago
Targeting a large addressable market in developing therapeutic compounds for pediatric diseases with unmet medical needs, Thiogenesis Therapeutics (TTI.v) is a clinical-stage biotech company: https://x.com/StckMasterFlash/status/1856131383535542718

Notably, TTI recently announced the approval of its European patent for the treatment of Cysteamine Sensitive Disorders, a medical condition characterized by cellular dysfunction, which complements the companys previous patent approvals in the US and Japan, as well as aligns with TTI's development of TTI-0102, a novel thiol-based prodrug designed to address mitochondrial diseases and related metabolic disorders by enhancing cellular antioxidant defenses.
👍️0
CommodityCoverage CommodityCoverage 1 month ago
Developing therapeutic compounds for pediatric diseases with unmet medical needs and a large addressable market, clinical-stage biotech company Thiogenesis Therapeutics (TTI.v), recently announced the approval of its European patent for the treatment of Cysteamine Sensitive Disorders, a medical condition characterized by cellular dysfunction: https://x.com/StckMasterFlash/status/1856131383535542718

Complementing previous patent approvals in the US and Japan, the IP protection aligns with TTI's development of TTI-0102, a novel thiol-based prodrug designed to address mitochondrial diseases and related metabolic disorders by enhancing cellular antioxidant defenses.
👍️0

Your Recent History

Delayed Upgrade Clock